Get the Stockscreener App
3.79
2.43%
0.09
After Hours:
3.80
0.010
+0.26%
Prime Medicine Inc stock is traded at $3.79, with a volume of 2.17M.
It is up +2.43% in the last 24 hours and up +3.84% over the past month.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
See More
Previous Close:
$3.70
Open:
$3.76
24h Volume:
2.17M
Relative Volume:
0.79
Market Cap:
$684.29M
Revenue:
$4.63M
Net Income/Loss:
$-201.14M
P/E Ratio:
-2.7582
EPS:
-1.3741
Net Cash Flow:
$-167.10M
1W Performance:
+7.06%
1M Performance:
+3.84%
6M Performance:
-40.50%
1Y Performance:
+187.12%
1-Day Range:
$3.655
$3.84
1-Week Range:
$3.27
$3.87
52-Week Range:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.79 | 668.04M | 4.63M | -201.14M | -167.10M | -1.3741 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Initiated | Oppenheimer | Outperform |
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Short Covering: Whats the fair value of Prime Medicine Inc stockTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Prime Medicine (NASDAQ:PRME) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Top Prime Medicine (PRME) Competitors 2026 - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 6.4%Here's What Happened - MarketBeat
Prime Medicine slips after Q4 updates - MSN
PRME PE Ratio & Valuation, Is PRME Overvalued - Intellectia AI
Stock Market Recap: Whats the fair value of Prime Medicine Inc stock2026 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Trend Review: Should I trade or invest in Prime Medicine Inc2026 Setups & Community Verified Swing Trade Signals - baoquankhu1.vn
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Prime Medicine, Inc. (NASDAQ:PRME) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Finviz
Bear Alert: Should I trade or invest in Prime Medicine Inc2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
S P Trends: Will Prime Medicine Inc stock hit new highs in YEARMarket Performance Summary & Precise Buy Zone Identification - baoquankhu1.vn
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3%What's Next? - MarketBeat
Prime Medicine (PRME) focuses on liver franchise with $191.4M cash runway - MSN
Prime Medicine (NASDAQ:PRME) Trading Up 5.6%Time to Buy? - MarketBeat
Support Test: Does Prime Medicine Inc have declining or rising EPSWeekly Risk Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Aug PostEarnings: Is Prime Medicine Inc a strong growth stock2026 Trade Ideas & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Prime Medicine, Inc. (PRME) reports Q4 loss, misses revenue estimates - MSN
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Hedge Fund Bets: Whats the fair value of Prime Medicine Inc stock2026 Institutional & Risk Managed Investment Entry Signals - baoquankhu1.vn
Farallon Capital Management LLC Buys 4,000,000 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Casdin Capital LLC Acquires 1,600,000 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Aug Weekly: Is Prime Medicine Inc backed by strong institutional buyingMarket Sentiment Review & Reliable Entry Point Alerts - baoquankhu1.vn
Oppenheimer Initiates Coverage on PRME with "Outperform" Rating - GuruFocus
Prime Medicine (NASDAQ:PRME) Shares Gap UpHere's Why - MarketBeat
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - MSN
Prime Medicine (NASDAQ:PRME) Trading Down 6.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Shares Down 6.9%Here's What Happened - MarketBeat
PRME Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
LifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseases - MSN
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway - Finviz
Will Prime Medicine Inc. stock outperform value stocksPrice Action & Technical Confirmation Alerts - Naître et grandir
Will Prime Medicine Inc. stock benefit from upcoming earnings reportsJuly 2025 Update & Growth Focused Entry Reports - Naître et grandir
10 Best New Penny Stocks to Buy - Insider Monkey
Guidance Update: Will Prime Medicine Inc stock hit new highs in YEARPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
HC Wainwright Predicts Stronger Earnings for Prime Medicine - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Lifesci Capital Predicts Prime Medicine FY2025 Earnings - MarketBeat
Prime Medicine, Inc. $PRME Shares Acquired by ARK Investment Management LLC - MarketBeat
Prime Medicine, Inc. $PRME Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat
[EFFECT] Prime Medicine, Inc. SEC Filing - Stock Titan
Citizens reiterates Prime Medicine stock rating on PM359 pathway - Investing.com Australia
Citizens reiterates Prime Medicine stock rating on PM359 pathway By Investing.com - Investing.com Canada
Prime Medicine (NASDAQ:PRME) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Prime Medicine unveils full year 2025 financial results and business update as progress advances - Traders Union
Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives - simplywall.st
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prime Medicine Inc Stock (PRME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):